UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: FMISO

First Posted Date: 2017-10-06

Last Posted Date: 2021-02-21

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 3

Registration Number: NCT03303469

Locations: 🇺🇸
UAB Advanced Imaging Facility, Birmingham, Alabama, United States

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Phase 2

Active, not recruiting

Conditions: Sedentary Lifestyle
Aging
Hypertension

Interventions: Behavioral: Aerobic exercise
Drug: Perindopril
Drug: Losartan
Drug: HCTZ

First Posted Date: 2017-09-28

Last Posted Date: 2024-05-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 213

Registration Number: NCT03295734

Locations: 🇺🇸
UAB Center for Exercise Medicine, Birmingham, Alabama, United States
🇺🇸
Translational Research Institute, Orlando, Florida, United States

A Resilience Building Intervention to Promote Successful Aging

Not Applicable

Completed

Conditions: Community Dwelling Adults Aged 50 and Older

Interventions: Behavioral: Pilot Resilience Building Intervention

First Posted Date: 2017-09-27

Last Posted Date: 2019-04-03

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 61

Registration Number: NCT03294655

Locations: 🇺🇸
the Holly Mears Building/Center for Research on Applied Gerontology, Birmingham, Alabama, United States

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form

Interventions: Drug: Treatment as Usual (TAU)
Drug: Autoantibody Reductive Therapy

First Posted Date: 2017-09-18

Last Posted Date: 2024-08-28

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 51

Registration Number: NCT03286556

Locations: 🇺🇸
Dan Dilling, Chicago, Illinois, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States

and more 4 locations

Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Counseling
Drug: combination NRT

First Posted Date: 2017-09-08

Last Posted Date: 2024-05-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 80

Registration Number: NCT03276780

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Diagnostic Test: [18F] Fluciclovine PET/MRI
Drug: [18F] fluciclovine

First Posted Date: 2017-08-29

Last Posted Date: 2020-03-09

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 18

Registration Number: NCT03264456

Locations: 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Ivacaftor/Ataluren

First Posted Date: 2017-08-22

Last Posted Date: 2019-07-19

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT03256799

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Understanding Value in Metastatic Breast Cancer

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2017-08-22

Last Posted Date: 2019-08-26

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 100

Registration Number: NCT03257917

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

High Resolution Micro OCT Imaging

Recruiting

Conditions: Cystic Fibrosis
PCD - Primary Ciliary Dyskinesia
Covid19
COPD
Sinusitis

First Posted Date: 2017-08-22

Last Posted Date: 2024-12-13

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 60

Registration Number: NCT03256773

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

PTC Study to Evaluate Ataluren in Combination With Ivacaftor

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Ataluren

First Posted Date: 2017-08-22

Last Posted Date: 2020-03-26

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT03256968

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy